The expression of 5T4 antigen in colorectal and gastric carcinoma
about
Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigenEmbryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epitheliaDevelopmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumorsCD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.Role of the epithelial-mesenchymal transition and its effects on embryonic stem cells.Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritisMetastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells.Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesisCD8 T-cell recognition of human 5T4 oncofetal antigen.An update on TroVax for the treatment of progressive castration-resistant prostate cancerE-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cellsPrognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancerCancer vaccines: a clinical perspective.Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Escalating regulation of 5T4-specific IFN-γ(+) CD4(+) T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.Naptumomab estafenatox: a new immunoconjugate.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies.Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.The function of e-cadherin in stem cell pluripotency and self-renewalVaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
P2860
Q24534036-516A4428-277C-42A2-9F18-224CD78A4A06Q28513567-8DA63733-8EDC-409F-BD5B-5C79EC3E1FF8Q28545761-97894988-7047-40C3-AE9A-EFB8EB5F43FDQ33268298-82DEE062-CB57-4423-BF6F-6A0C8BEDD8FAQ34116239-04691F5B-AF9E-4043-A1D2-8F9A973CB20BQ34354544-01C9C0F7-6983-4DE1-9886-D8ECF73F6F41Q34405136-AFE9D89A-A72B-46B6-B3CC-5528EC4F12E8Q34423998-A9C81C6D-E062-4C6D-9E4D-6503CB614479Q34518944-056FF98A-FFFC-4DDA-A5C3-9D51CE7296F6Q35050205-F16E8B63-80DF-4B20-A2D2-167CF853F1A6Q35942348-38B4EF84-E7D2-4F92-9DCB-5FBF2A40CB15Q35978519-9DB7845F-C7AB-4928-B494-4F94B9B3AF3CQ36073267-577783CB-E6F6-40D9-B37E-4EDFC3F5ED25Q36554683-A79C0811-25D1-45B7-808E-B54566D0E05FQ36623092-642C7F1B-05B4-4CC7-AA7D-8BD8AEB5159DQ37074226-E6B37EBB-B06A-49FF-95E8-CCCA2478F238Q37434041-95362C7F-D8F9-4E24-A960-C8142A232DE8Q37669341-BB5E7C55-3B93-44DB-8769-C190061B0219Q38123176-ACD67081-97F6-40F6-BF0C-45EC9C7300C5Q38180315-2B8BFFBD-46E9-493E-93A2-9F07140FCF7FQ38984929-DC647D9B-B022-4F2C-AC26-2766E863BFA9Q40062688-1EB4523B-045A-41F9-96A9-08C6388E87D1Q40289394-47D4B388-39DD-4BDB-A676-502F3694497BQ40445773-D838F6D3-B768-4F08-9BCB-E22CE848C46AQ40696514-2C79AE45-3AD9-4FE2-8177-113E9CD072CEQ40732932-C05FFB56-D57E-47DA-B2D4-E94FF8679300Q41956122-1D3082DF-8C46-4D7B-954D-20EF0ACB0AD6Q42638914-9ED530A3-F2C5-4A87-8CFF-2A8C69DC7A84Q49843670-4FE66023-FA9F-4C67-BFB1-F77FA4505D07Q51817562-D4C15FC6-AC42-4B29-B0D7-3CC62C742BED
P2860
The expression of 5T4 antigen in colorectal and gastric carcinoma
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The expression of 5T4 antigen in colorectal and gastric carcinoma
@ast
The expression of 5T4 antigen in colorectal and gastric carcinoma
@en
The expression of 5T4 antigen in colorectal and gastric carcinoma
@nl
type
label
The expression of 5T4 antigen in colorectal and gastric carcinoma
@ast
The expression of 5T4 antigen in colorectal and gastric carcinoma
@en
The expression of 5T4 antigen in colorectal and gastric carcinoma
@nl
prefLabel
The expression of 5T4 antigen in colorectal and gastric carcinoma
@ast
The expression of 5T4 antigen in colorectal and gastric carcinoma
@en
The expression of 5T4 antigen in colorectal and gastric carcinoma
@nl
P2093
P2860
P356
P1476
The expression of 5T4 antigen in colorectal and gastric carcinoma
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1992.375
P407
P577
1992-11-01T00:00:00Z
P5875
P6179
1005644395